Baker Brothers Advisors - Q4 2022 holdings

$16.7 Billion is the total value of Baker Brothers Advisors's 113 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 26.1% .

 Value Shares↓ Weighting
SGEN  Seagen Inc.$6,028,695,304
-6.1%
46,912,2660.0%36.20%
-13.9%
INCY BuyIncyte Corporation$2,903,967,271
+20.5%
36,154,971
+0.0%
17.44%
+10.5%
BGNE  BeiGene, Ltd.sponsored adr$2,566,457,206
+63.1%
11,668,8970.0%15.41%
+49.6%
BMRN  BioMarin Pharmaceutical Inc.$788,644,924
+22.1%
7,620,4940.0%4.74%
+11.9%
ACAD  ACADIA Pharmaceuticals Inc.$667,421,897
-2.7%
41,923,4860.0%4.01%
-10.8%
ASND BuyAscendis Pharma A/Ssponsored adr$605,136,441
+20.8%
4,954,855
+2.1%
3.63%
+10.7%
MDGL BuyMadrigal Pharmaceuticals, Inc.$448,469,048
+360.3%
1,545,113
+3.1%
2.69%
+322.1%
RYTM BuyRhythm Pharmaceuticals, Inc.$185,046,185
+24.6%
6,354,608
+4.8%
1.11%
+14.2%
BCRX  BioCryst Pharmaceuticals, Inc.$145,920,191
-8.9%
12,710,8180.0%0.88%
-16.5%
IMCR  Immunocore Holdings plcads$143,858,118
+21.6%
2,520,7310.0%0.86%
+11.5%
AKRO  Akero Therapeutics, Inc.$129,787,114
+60.9%
2,368,3780.0%0.78%
+47.5%
REPL BuyReplimune Group, Inc.$124,529,216
+85.2%
4,578,280
+17.6%
0.75%
+70.0%
KOD  Kodiak Sciences Inc.$123,943,108
-7.5%
17,310,4900.0%0.74%
-15.2%
HZNP  Horizon Therapeutics Public Ltd Co$110,354,933
+83.9%
969,7270.0%0.66%
+68.7%
ARGX  argenx SEsponsored adr$106,132,634
+7.3%
280,1590.0%0.64%
-1.7%
ABCL  AbCellera Biologics Inc.$105,860,323
+2.4%
10,450,1800.0%0.64%
-6.1%
KYMR  Kymera Therapeutics, Inc.$71,880,432
+14.7%
2,879,8250.0%0.43%
+5.1%
KDNY  Chinook Therapeutics, Inc.$66,393,472
+33.3%
2,534,1020.0%0.40%
+22.4%
 Entrada Therapeutics, Inc.$65,785,873
-14.2%
4,865,8190.0%0.40%
-21.3%
MRTX  Mirati Therapeutics, Inc.$63,877,313
-35.1%
1,409,7840.0%0.38%
-40.5%
PRLD  Prelude Therapeutics Inc.$61,147,897
-8.6%
10,123,8240.0%0.37%
-16.2%
CERS  Cerus Corporation$58,646,587
+1.4%
16,067,5580.0%0.35%
-7.1%
AVTE SellAerovate Therapeutics, Inc.$57,922,232
+76.5%
1,976,868
-0.1%
0.35%
+61.9%
IGMS  IGM Biosciences, Inc.$53,685,295
-25.2%
3,156,1020.0%0.32%
-31.5%
IMTX BuyImmatics N.V.$45,179,476
+2.1%
5,187,081
+17.3%
0.27%
-6.6%
NRIX  Nurix Therapeutics, Inc.$42,625,733
-15.7%
3,882,1250.0%0.26%
-22.7%
KNSA  Kiniksa Pharmaceuticals, Ltd.$41,937,663
+16.7%
2,799,5770.0%0.25%
+7.2%
SWTX NewSpringWorks Therapeutics, Inc.$39,757,2731,528,538
+100.0%
0.24%
IDYA  IDEAYA Biosciences, Inc.$30,314,010
+21.8%
1,668,3550.0%0.18%
+11.7%
DNLI BuyDenali Therapeutics Inc.$30,277,804
+67.6%
1,088,738
+84.9%
0.18%
+54.2%
XENE  Xenon Pharmaceuticals Inc.$29,637,126
+9.2%
751,6390.0%0.18%0.0%
VERV  Verve Therapeutics, Inc.$27,409,856
-43.7%
1,416,5300.0%0.16%
-48.3%
BuyDICE Therapeutics, Inc.$26,900,858
+125.5%
862,207
+46.6%
0.16%
+107.7%
TVTX SellTravere Therapeutics, Inc.$25,767,113
-68.3%
1,225,255
-62.9%
0.16%
-70.9%
BCYC  Bicycle Therapeutics plcsponsored ads$24,976,894
+27.3%
843,8140.0%0.15%
+16.3%
ANAB BuyAnaptysBio, Inc.$24,045,885
+120.7%
775,924
+81.6%
0.14%
+102.8%
KRYS SellKrystal Biotech, Inc.$23,981,162
-18.5%
302,716
-28.3%
0.14%
-25.4%
DBVT  DBV Technologies S.A.sponsored adr$22,359,824
-13.6%
14,614,2640.0%0.13%
-20.7%
FGEN BuyFibroGen, Inc.$22,030,880
+107.6%
1,375,211
+68.6%
0.13%
+91.3%
RARE  Ultragenyx Pharmaceutical Inc.$21,820,225
+11.9%
470,9740.0%0.13%
+2.3%
HRTX  Heron Therapeutics, Inc.$20,329,195
-40.8%
8,131,6780.0%0.12%
-45.8%
 2seventy bio, Inc.$19,327,911
-35.6%
2,062,7440.0%0.12%
-41.1%
SellInsmed Incorporatednote 0.75% 6/1/2028$19,229,604
-47.0%
23,500,000
-41.2%
0.12%
-51.7%
NewPrime Medicine, Inc.$19,108,8981,028,466
+100.0%
0.12%
BMEA  Biomea Fusion, Inc.$17,741,432
-13.8%
2,104,5590.0%0.11%
-20.7%
BLUE  bluebird bio, Inc.$17,298,028
+9.3%
2,499,7150.0%0.10%0.0%
SBTX NewARS Pharmaceuticals, Inc.$17,115,0272,006,451
+100.0%
0.10%
NVTA  Invitae Corporation$15,627,785
-24.4%
8,402,0350.0%0.09%
-30.4%
OPT  Opthea Limitedsponsored ads$14,425,856
-13.6%
2,691,3910.0%0.09%
-20.2%
ADAP  Adaptimmune Therapeutics plcsponsored adr$14,353,080
+35.8%
9,830,8770.0%0.09%
+24.6%
CBAY  CymaBay Therapeutics, Inc.$13,608,809
+79.1%
2,170,4640.0%0.08%
+64.0%
NewZymeworks Inc.$13,428,5901,708,472
+100.0%
0.08%
 Aadi Bioscience, Inc.$12,700,776
-9.2%
989,9280.0%0.08%
-17.4%
CABA BuyCabaletta Bio, Inc.$12,432,000
+2791.2%
1,344,000
+103.0%
0.08%
+2400.0%
ALT SellAltimmune, Inc.$10,751,095
-52.4%
653,562
-63.1%
0.06%
-56.1%
VSTM  Verastem, Inc.$10,863,032
-52.6%
26,988,8980.0%0.06%
-56.7%
STOK BuyStoke Therapeutics, Inc.$10,235,267
+115.8%
1,108,913
+200.3%
0.06%
+96.8%
 CinCor Pharma, Inc.$9,920,635
-62.6%
807,2120.0%0.06%
-65.5%
VOR  Vor Biopharma Inc.$9,748,401
+67.1%
1,465,9250.0%0.06%
+55.3%
RNA NewAvidity Biosciences, Inc.$9,647,813434,782
+100.0%
0.06%
PACB  Pacific Biosciences of California, Inc.$9,225,257
+40.9%
1,127,7820.0%0.06%
+27.9%
RETA  Reata Pharmaceuticals, Inc.cl a$8,508,848
+51.2%
223,9760.0%0.05%
+37.8%
VERU  Veru Inc.$8,498,577
-54.2%
1,609,5790.0%0.05%
-57.9%
SMMT NewSummit Therapeutics Inc.$8,500,0002,000,000
+100.0%
0.05%
PNT  POINT Biopharma Global Inc.$8,522,761
-5.7%
1,169,1030.0%0.05%
-13.6%
AFMD  Affimed N.V.$8,180,069
-39.8%
6,596,8300.0%0.05%
-44.9%
 Invitae Corporationnote 2.0% 9/1/2024$8,058,143
-1.1%
10,300,0000.0%0.05%
-9.4%
CMPX NewCompass Therapeutics, Inc.$7,834,8791,557,630
+100.0%
0.05%
DSGN SellDesign Therapeutics, Inc.$7,101,264
-70.4%
692,131
-51.8%
0.04%
-72.6%
NewBiohaven Ltd.$6,609,517476,190
+100.0%
0.04%
VERA  Vera Therapeutics, Inc.cl a$6,449,994
-9.2%
333,3330.0%0.04%
-17.0%
ALEC BuyAlector, Inc.$6,294,777
+178.2%
681,991
+185.1%
0.04%
+153.3%
ATHA BuyAthira Pharma, Inc.$5,959,080
+92.8%
1,879,836
+80.6%
0.04%
+80.0%
MGNX  MacroGenics, Inc.$5,989,205
+94.0%
892,5790.0%0.04%
+80.0%
IPSC BuyCentury Therapeutics, Inc.$5,896,114
+60.9%
1,149,340
+210.1%
0.04%
+45.8%
NewRoivant Sciences Ltd.$5,726,057716,653
+100.0%
0.03%
 Tango Therapeutics, Inc.$5,437,500
+100.3%
750,0000.0%0.03%
+83.3%
RVMD  Revolution Medicines, Inc.$5,293,328
+20.8%
222,2220.0%0.03%
+10.3%
EWTX  Edgewise Therapeutics, Inc.$4,470,000
-9.1%
500,0000.0%0.03%
-15.6%
PRAX NewPraxis Precision Medicines, Inc.$4,356,1501,830,315
+100.0%
0.03%
 TScan Therapeutics, Inc.$4,316,428
-49.2%
2,784,7920.0%0.03%
-53.6%
ARAV NewAravive, Inc.$4,304,8163,261,224
+100.0%
0.03%
CYT SellCyteir Therapeutics, Inc.$4,111,995
-19.0%
2,492,118
-5.7%
0.02%
-24.2%
NTRA  Natera, Inc.$4,017,000
-8.3%
100,0000.0%0.02%
-17.2%
TIL BuyInstil Bio, Inc.$3,322,487
-82.4%
5,273,789
+35.4%
0.02%
-83.7%
TLIS  Talis Biomedical Corporation$3,398,389
-34.6%
7,624,8350.0%0.02%
-41.2%
XNCR NewXencor, Inc.$3,206,227123,127
+100.0%
0.02%
ITOS  iTeos Therapeutics, Inc.$2,936,257
+2.5%
150,3460.0%0.02%
-5.3%
NewKala Pharmaceuticals, Inc.$2,930,41676,813
+100.0%
0.02%
PMVP  PMV Pharmaceuticals, Inc.$2,801,609
-26.9%
322,0240.0%0.02%
-32.0%
BCEL  Atreca, Inc.$2,828,328
-49.0%
3,532,7600.0%0.02%
-52.8%
HOOK BuyHOOKIPA Pharma Inc.$2,815,183
-12.5%
3,475,535
+44.8%
0.02%
-19.0%
ATRA  Atara Biotherapeutics, Inc.$2,440,930
-13.2%
744,1860.0%0.02%
-16.7%
PCVX NewVaxcyte, Inc.$2,344,03648,885
+100.0%
0.01%
ACHL  Achilles Therapeutics plcsponsored ads$2,332,229
-60.2%
2,591,3660.0%0.01%
-63.2%
NKTX  Nkarta, Inc.$2,396,000
-54.5%
400,0000.0%0.01%
-58.8%
FATE  Fate Therapeutics, Inc.$2,176,363
-55.0%
215,6950.0%0.01%
-59.4%
NLTX  Neoleukin Therapeutics, Inc.$1,945,266
-20.5%
3,821,7400.0%0.01%
-25.0%
KRON SellKronos Bio, Inc.$1,941,005
-62.4%
1,198,151
-22.2%
0.01%
-64.7%
ALGS  Aligos Therapeutics, Inc.$1,978,602
-13.4%
2,076,4000.0%0.01%
-20.0%
AGLE  Aeglea BioTherapeutics, Inc.$1,534,207
-14.5%
3,410,1060.0%0.01%
-25.0%
TCRR  TCR2 Therapeutics Inc.$752,160
-44.5%
753,0640.0%0.01%
-44.4%
TARA  Protara Therapeutics, Inc.$535,118
-9.5%
199,6710.0%0.00%
-25.0%
KZR  Kezar Life Sciences, Inc.$436,100
-18.2%
61,9460.0%0.00%0.0%
GTH  Genetron Holdings Limitedads$509,943
+43.2%
455,3060.0%0.00%
+50.0%
 Sera Prognostics, Inc.$253,968
-21.1%
201,5620.0%0.00%0.0%
FHTX  Foghorn Therapeutics Inc.$287,272
-25.6%
45,0270.0%0.00%
-33.3%
LPTX  Leap Therapeutics, Inc.$251,867
-48.9%
559,7050.0%0.00%
-33.3%
INSM  Insmed Incorporated$398,601
-7.3%
19,9500.0%0.00%
-33.3%
VINC  Vincerx Pharma, Inc.$246,207
-26.1%
241,3790.0%0.00%
-50.0%
 Bellicum Pharmaceuticals, Inc.$179,369
-40.0%
249,1230.0%0.00%
-50.0%
 Surrozen, Inc.w exp 8/11/2026$45,917
-70.2%
833,3330.0%0.00%
-100.0%
LIFE SellaTyr Pharma, Inc.$18,757
-96.9%
8,565
-95.7%
0.00%
-100.0%
LOGC ExitLogicBio Therapeutics, Inc.$0-139,105
-100.0%
0.00%
OTIC ExitOtonomy, Inc.$0-8,443,134
-100.0%
-0.02%
SNDX ExitSyndax Pharmaceuticals, Inc.$0-110,729
-100.0%
-0.02%
EIGR ExitEiger BioPharmaceuticals, Inc.$0-539,851
-100.0%
-0.03%
ALLK ExitAllakos Inc.$0-703,050
-100.0%
-0.03%
ExitSurrozen, Inc.$0-2,500,000
-100.0%
-0.03%
AMRN ExitAmarin Corporation plcsponsored adr$0-5,377,113
-100.0%
-0.04%
FLGT ExitFulgent Genetics, Inc.$0-166,619
-100.0%
-0.04%
ZYME ExitZymeworks Inc.$0-1,708,472
-100.0%
-0.07%
TCDA ExitTricida, Inc.$0-1,320,290
-100.0%
-0.09%
CRNX ExitCrinetics Pharmaceuticals, Inc.$0-735,716
-100.0%
-0.10%
ALKS ExitAlkermes plc$0-815,016
-100.0%
-0.12%
RLMD ExitRelmada Therapeutics, Inc.$0-495,113
-100.0%
-0.12%
FMTX ExitForma Therapeutics Holdings, Inc.$0-1,886,760
-100.0%
-0.25%
CCXI ExitChemoCentryx, Inc.$0-1,792,657
-100.0%
-0.61%
GBT ExitGlobal Blood Therapeutics, Inc.$0-3,732,502
-100.0%
-1.66%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-02-14
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation42Q3 202337.6%
ACADIA Pharmaceuticals Inc.42Q3 202310.9%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
BioCryst Pharmaceuticals, Inc.42Q3 20231.7%
Cerus Corporation42Q3 20230.9%
Insmed Incorporated42Q3 20230.4%
Mirati Therapeutics, Inc.41Q3 20231.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
ChemoCentryx, Inc.37Q3 20220.6%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q4 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.August 17, 20239,469,83820.0%
Mereo Biopharma Group plcAugust 10, 202314,604,3912.2%
Verastem, Inc.August 10, 2023? ?
TScan Therapeutics, Inc.June 02, 20232,793,9386.5%
ACADIA PHARMACEUTICALS INCMay 24, 202343,084,28026.5%
INCYTE CORPMarch 15, 202336,280,96716.3%
Seagen Inc.March 13, 202346,985,65625.1%
Talis Biomedical CorpMarch 10, 202337,569,14066.2%
Aeglea BioTherapeutics, Inc.February 14, 20236,384,0139.9%
Merus N.V.February 14, 2023? ?

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-25
SC 13D/A2024-03-25
42024-03-14
32024-03-07
42024-03-07
SC 13D2024-03-05
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings